Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or refractory CLL in a phase I/II study. A standard phase I design was used with cohorts of three plus three patients to determine the maximum tolerated dose (MTD) of MK-2206 in combination with BR in relapsed CLL. Single-agent MK-2206 (weekly dosed) was administered one-week in advance before BR on cycle 1 and subsequently was given with BR at the same time for cycle 2-6. Phase II employed the MTD of MK-2206 with BR to evaluate safety and efficacy of this study combination. Thirteen relapsed/refractory CLL were treated for maximal 6-cycle of therapy. The maximum tolerated dose of MK-2206 was 90 mg by mouth once weekly. The most common grade 3/4 adverse events were neutropenia (46%), febrile neutropenia (23%), rash (15%), diarrhea (15%), and thrombocytopenia (15%). Overall response rate was 92% with a median progression free survival and treatment free survival of 16 and 24 months, respectively. Five patients (38%) achieved complete remission or complete remission with incomplete count recovery, two of whom were MRD negative. The efficacy and tolerability of this combination indicates that Akt inhibition combined with chemoimmunotherapy is a promising novel treatment combination in CLL and deserves further prospective clinical trial.
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| I N T R O D U C T I O N
An improved understanding of the fundamental role of B-cell receptor (BCR) activation in the biology of CLL has led to major breakthroughs of new therapies including the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib 1 and Phosphoinositide-3 Kinase (PI3K) d inhibitor idelalisib. 2 The protein serine/threonine kinase Akt is a downstream target of BCR, PI3K, and growth factor receptor signaling pathways and is a central regulator of apoptosis, proliferation, and metabolism. In addition
Akt activation results in phosphorylation of targets capable of promoting cell-cycle, stimulating cell metabolism, and antagonism of proapoptotic proteins. Importantly constitutive Akt activity is observed in CLL/SLL 3 and is known to be triggered through BCR ligation and cytokine stimulation 4, 5 and can also occur via bi-directional interactions between the CLL cells and the microenvironment leading to a promotion of cell survival and growth. 6, 7 In addition Increased Akt activation through PI3K pathway signaling as well as PI3K-independent pathways such as PKCb 8 enhances CLL cell viability and chemotherapy resistance.
Notably, direct Akt inhibition has been shown to result in death of CLL cells even within protective niches including CLL B cell clones designated as high risk with unmutated IgVH genes, del (17p) and high CD38 expression. 9 This latter finding adds to the attractive possibility that targeting Akt in CLL B cells will be of benefit in therapy of this disease. 
| M E T H O D S
The 
| Safety
Patients received a median of 6 cycles (range: 1-6). A total of 9 patients were treated in the phase 1 portion of the trial. Six patients were One patient discontinued after one cycle due to progressive disease.
In all 13 evaluable patients, the most frequent grade 3 or 4 treatment-related adverse events observed in >1 patient were neutropenia (46%), febrile neutropenia (23%), rash (15%), diarrhea (15%), and thrombocytopenia (15%). A grade 3/4 treatment-related adverse event of nausea and vomiting, dehydration, sinusitis, hemolysis, or tumor lysis syndrome was observed in one patient each. The most frequent nonhematologic treatment-related adverse event of any grade (reported in 10%) were: nausea (54%), diarrhea (39%), rash (39%), vomiting (31%), hyperglycemia (31%, all grade 1), oral mucositis (23%), fatigue (15%), fever (15%) and sinus bradycardia (15%) as shown in Table 2 .
| Efficacy
Considering all 13 patients in the study, 12 (92%; 95% CI: 64% -99.8%) experienced a response including 5 (38%, 95% CI: 14%-68%) who achieved CR/CRi at the time of response evaluation (Table 3) 
| DISCUSSION
In this early phase study, we demonstrate that Akt inhibition with MK-2206 in combination with BR in relapsed and/or refractory CLL patients is tolerable and active. This above combination resulted in an CR/CRi rate 38%, PFS and TFS being 16 and 25 months respectively. These data at least compare similarly to, if not better than, the previous reported experience with BR in relapsed CLL. 13 In this previous study, an ORR of 60%, a CR rate of 9% and an event free survival being 15 months were observed. In an effort to improve the efficacy of BR-based therapy, combination of targeted therapy using ibrutinib or idelalisib with BR were tested. The CR rate in trials evaluating the combination of ibrutinib with BR [16] [17] [18] and idelalisib with BR 19 were 20% and 10%
before the single-agent extension phase, respectively. It is notable that these trials also included maintenance ibrutinib/idelalisib as single-agent extension after BR combination whereas in our study MK2206 was stopped after 6 cycles of BR combination. The differences in the duration of therapy in our trial were likely the causes for the shorter PFS observed in this study compared to the longer PFS seen with the trials used BR and ibrutinib combination. [16] [17] [18] This current study was initially designed to assess the synergy of Akt inhibition with BR chemotherapy and thus was not designed to have a maintenance therapy of Akt inhibitor to assess the effect of Akt inhibition on the PFS of this combination.
Novel targeted therapy has changed the landscape of CLL therapy.
International phase 3 studies to compare the efficacy of front-line chemoimmunotherapy with ibrutinib-based therapy have been ongoing and results are eagerly waited. Despite the excellent efficacy of novel targeted therapy in relapsed CLL patients, a significant portion of CLL patients continue to progress or stop therapy due to intolerability. 20, 21 How to manage these patients is an active area of CLL research. It is to be determined whether progressive CLL patients after prior targeted therapies can still respond to chemoimmunotherapy or combination of targeted therapy with chemotherapy. Our early phase trial presented in this study provided an initial proof-of-concept of the combination therapy using Akt inhibitor with BR though none of the patients in this study had prior targeted therapy. The primary limitation of our study is the small sample size as patient accrual was terminated early due to the drug-sponsor's decision to discontinue further MK-2206 development. Nonetheless with the favorable efficacy results and tolerability of Akt inhibition in combination with BR in the relapsed or refractory CLL cohort in this trial, further prospective testing of Akt inhibitors in CLL appears warranted.
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FIG URE 1 PFS and OS curve. PFS is defined to be the time from registration to the date of progression or death or last follow-up. OS is defined to be the time from registration to the date of death or last follow-up
